Cabotegravir
Vocabria (cabotegravir) is a small molecule pharmaceutical. Cabotegravir was first approved as Vocabria on 2020-12-17. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. Cabenuva's patent is valid until 2026-04-28 (FDA).
| Trade Name | Vocabria |
|---|---|
| Common Name | Cabotegravir |
| Indication | hiv infections |
| Drug Class | Antivirals: integrase inhibitors |
